How To Manage Your Mucormycosis Patients?

June 13, 2021

The second wave of COVID-19 infections complicated patient management beyond expected and also saw a surge in the fungal infections, many proving fatal. These fungal infections, that are attributed to a group called mucormycetes are commonly found in our environment and are not naturally harmful in most people. However, there was a marked spread of these opportunistic infections in COVID-19 patients with pre-existing health conditions such as diabetes or who were using medicines that compromised their immune response.
The two types of mucormycetes responsible for most cases of Mucormycosis were Rhino-orbito-cerebral Mucormycosis (ROCM) and Pulmonary Mucormycosus. 

To learn more from experiences of experts (scientists and clinicians) working behind their microscopes and on patients with Mucormycosis, the Medical Learning Hub started a webinar series that saw thousands of clinicians participate during May 2021. Simply click “Get Started” on the course pages of these experience sharing events to learn more about this topic:

May 20th | Mucormycosis aka Black Fungus: Case Presentation & Clinical Management | Host: IMA Maharashtra | Speakers: Dr Arunaloke Chakarbarti (PGIMER) & Dr. Sanjib Badhwar (Kokilaben) |

May 29th | COVID & Mucormycosis | Host: IMA UP | Speakers: Dr Alok Thakar (AIIMS) & Dr. Santosh G Honavar (Center for Sight) | 

To attend an upcoming event on Mucormycosis, register for an event here: